Celgene's 19% year-over-year increase in first quarter net product sales was driven by hematology and oncology products, but alongside its January-to-March earnings report the company announced a $710m investment to diversify its portfolio and expand its…
written on 25.04.2014
1Q EARNINGS: Celgene boosts sales, bets big on Crohn's drug
Latest Reports
The Technology Driving Rare Disease Pipelines
Rhenu Buller, an expert on disruptive technologies at business consultancy Frost & Sullivan’s Asia…
Sandoz: CEO Quits, Spinoff Rumours Swirl
Richard Francis, CEO of Sandoz will step down at the end of the March. The abrupt announcement will fan the flames…
Evolutionary Trends in Pharmacy Technology
Meghann Chilcott, Chief Technology/Marketing Officer at Benzer Pharmacy charts out new pathways for improving the…